Table 3.
The association between TAF1L overexpression and clinicopathological characteristics of ESCC
| Clinicopathological characteristics | Case numbers | Overexpression | ||
|---|---|---|---|---|
| Yes (n) | No (n) | p-value | ||
| Age(years) | ||||
| <60 | 87 | 61 | 26 | 0.8615 |
| ≥60 | 63 | 45 | 18 | |
| Gender | ||||
| Female | 43 | 26 | 17 | 0.0819 |
| Male | 107 | 80 | 27 | |
| Differentiation | ||||
| Well | 49 | 33 | 16 | 0.6359 |
| Moderate | 55 | 39 | 16 | |
| Poor | 42 | 32 | 10 | |
| Stage | ||||
| Ⅰ | 12 | 8 | 4 | 0.2413 |
| Ⅱ | 78 | 51 | 27 | |
| Ⅲ | 60 | 47 | 13 | |
| TNM-T | ||||
| T1-2 | 32 | 19 | 13 | 0.1137 |
| T3 | 118 | 87 | 31 | |
| TNM-N | ||||
| N0 | 86 | 54 | 32 | 0.0141* |
| N1-2 | 64 | 52 | 12 | |
| TNM-M | ||||
| M0 | 110 | 74 | 36 | 0.7940 |
| M1 | 40 | 26 | 14 | |
* It indicated statistically significant p<0.05.